vaccine
Congenital cytomegalovirus (CMV) infection is the leading non-genetic cause of sensorineural hearing loss, and CMV infection affects 0.2%-2.2% of live births in industrialized countries (1, 2) . Pre-existing maternal antibodies to CMV is the most important protective factor against congenital CMV infection, and primary CMV infection is more likely than non-primary infection to cause symptoms at birth and long-term disability (3). However, the seroprevalence among pregnant women ranges between 65% and 87% and has recently been decreasing in Japan (4, 5) .
Congenital rubella syndrome (CRS) is rare in developed countries as a result of established rubella immunization programs. However, in Japan, there was a large outbreak of rubella in 2012-2013. More than 16,000 cases of rubella and 45 infants with CRS were reported from 2012 to 2014 through the National Epidemiological Surveillance of Infectious Diseases (6).
Prevention of mother-to-child transmission is extremely important, and transplacental maternal antibodies are important in the prevention and alleviation of viral infections in the fetus and neonate. The aim of this study The virus seroprevalence in the umbilical cord blood samples was as follows: HSV, 54%; VZV, 96%; EBV, 96%; CMV, 67%; HHV-6, 100%; MV, 95%; RV, 94%; MuV, 64%; and HPV B19, 55% ( Of the 561 mothers, 501 (89%) completed the questionnaire. Vaccination coverage among mothers who received at least one dose was as follows: varicella, 17%; measles, 53%; rubella, 38%; and mumps, 26% (Table 3) . These rates were found to be significantly higher than those observed in 2001-2002.
The previous infection rates of the mothers were as follows: varicella, 82%; measles, 33%; rubella, 37%; and mumps, 54% (Table 3 (Table 4) .
Discussion
In recent years, the mean age of the pregnant woman is increasing in Japan. According to the Population Survey Report from Ministry of Health,
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Labour and Welfare, mean childbearing age had risen to 31.6 years in 2013 from 29.7 years in 2001. Consistent with this, our study also found an increase in the mean maternal age. In addition, we found that the seroprevalence of HSV, CMV, MuV, and HPV B19 in umbilical cord blood was relatively low in this time-series analysis investigating sero-status of nine viral species. Moreover, a significant decrease in seropositivity for CMV, MV, and MuV was seen over time. When examining the seroprevalence according to maternal age, some significant findings were observed in several viruses, but no consistent trends were observed with respect to the maternal age.
The seroprevalence of HSV was reduced considerably in Japan from the 1970s through the 1990s (8) . In recent years, the Japanese seropositive rate for HSV-1 and HSV-2 in females was reported 63.3% and 9.3%, which is similar to that reported in other developed countries (9) . This study revealed that the seroprevalence of HSV was 53%, comparable with a recent report, and has continued to be a relatively low value over the past twelve years.
Neonatal HSV infection causes serious morbidity and mortality, leaving many survivors with permanent sequelae. The incidence of neonatal herpes infection varies widely from 1.6 to 33 per 100,000 live births, being 2.6 in Japan (10-12). First-time infection of the mother is the most important factor for transmission of genital herpes from the mother to the fetus or the newborn. The incidence of neonatal HSV infection in the UK was reported to increase 11-fold over the past two decades with a significant rise in first-episode genital herpes (13) . In Japan, however, the number of reports of A c c e p t e d M a n u s c r i p t female genital herpes infection has roughly unchanged in the last decade, and the incidence of neonatal herpes has declined compared with the previous national survey (12, 14) .
CMV is the most common congenital viral infection, with a birth prevalence of about 0.2%-2.2% in developed countries and 0.31% in Japan (1,2,15) . Congenital CMV infection causes significant clinical consequences not only at birth but also later, presenting as neurological sequelae, including sensorineural hearing loss and developmental delay. The seroprevalence of CMV increases with age depending on geographic area and socioeconomic status. CMV seroprevalence was reported to have been decreasing recently in Japan (4). In this study, the seropositive rate for CMV was significantly decreased from 76% in 2001-2002 to 67% in 2013, and this result is similar to previous reports (4, 5) . Though significant congenital morbidity occurs following both primary and non-primary maternal infection, the presence of maternal antibodies to CMV is the most important protective factor against congenital CMV infection (3). Because CMV seroprevalence has been decreasing in Japan, measures to prevent CMV infection in reproductive women has become extremely important.
Intrauterine infections with EBV and HHV-6 are regarded not to be related to congenital anomalies. In addition, the maternal seroprevalence of EBV and HHV-6 identified in this study has been maintained at more than 95% over the past 12 years. Hence, intrauterine infections with these viruses are considered rare.
HPV B19 infection during pregnancy is associated with fetal death, particularly in the first half of pregnancy. In addition to causing fetal loss, HPV B19 is cytotoxic to fetal red cell precursors and may cause anemia and hydrops fetalis. Antibodies to HPV B19 are found in 30%-80% of adults (16) (17) (18) . This study found that the seroprevalence of HPV B19 was 54% and comparable with data from another report from Japan (19) and were lower than those observed in females (20) . The seroprevalence discrepancy was considered to be the result of the past immunization policies for rubella in Japan. Since 2006, a measles-rubella vaccine has been administered to both boys and girls at the age of 1 year and in the preschool years. The vaccination rate in the first phase has recently maintained more than 95%, so it will be maintained at a high seropositivity rate without In this study, we used the umbilical cord blood, because collecting umbilical cord blood samples is non-invasive to both mothers and neonates.
The antibody levels of umbilical cord blood are similar or higher than those of the mother (21) (22) (23) . In order to investigate the maternal seroprevalence, there are no issues related to using umbilical cord blood.
There have been several studies reporting the seroprevalence of various viruses in Japanese pregnant women; however, these studies investigated only a few viruses. The advantage of this study is that we investigated a wide variety of viruses, up to nine species. Furthermore, we also analyzed the development of seroprevalence over time. Thus, the findings of this study will be valuable in terms of informing policies related to mother-to-child infection control. The limitation of this study is that the data pertaining to past history and maternal immunization depended on a questionnaire. The rate of mothers who were able to confirm their immunization record was not even 30%. However, there were not many differences between the entire results and those of mothers who confirmed their immunization record.
Hence, we consider our findings rather reliable. A c c e p t e d M a n u s c r i p t 
